SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is seeing high volatility as investors weigh a strong earnings beat and a new 4-for-1 stock split against concerns that its rapid growth and premium valuation are stretching expectations too far. The community is actively debating whether to treat the recent post-earnings pullback as a buying opportunity in a long-term cybersecurity leader or as a sign of deeper structural cooling in software valuations.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is currently a focal point for the community following its strategic decision to shut down internal discovery operations and close its Alabama facility in a pivot toward a more capital-efficient model focused on external partnerships. Investors are intensely debating whether this move signifies an effort to make the company a leaner, more attractive bolt-on acquisition target or if it signals an end to the long-standing hope for a massive buyout premium.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is currently trending as a defensive anchor for investors amid a broader market rotation, with its strong portfolio of pharmaceutical and medical technology assets driving a push toward all-time highs. The community is actively discussing J&J's consistent dividend profile, potential acquisitions to strengthen its oncology pipeline, and the persistent legal overtones regarding talc litigation that continue to shape market sentiment.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently seeing heightened investor interest and increased trading volume as the market reacts to shifting narratives around its silicon-anode battery technology for emerging AI edge devices, drones, and smart glasses. The community remains deeply divided between long-term bulls encouraged by recent commercial scaling milestones and potential supply chain partnerships, and skeptics who remain focused on historical production delays and the pressure to prove execution at scale.

SharonAI Holdings, Inc. operates as a holding company that develops and delivers GPU cloud computing and AI solutions. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is currently experiencing intense market interest driven by a strategic pivot toward becoming a sovereign AI infrastructure provider, bolstered by a massive multi-year compute collaboration with NVIDIA. Community sentiment is heavily focused on the company's tight float, significant contracted pipeline in the APAC region, and strategic positioning as a neocloud play, with active discussion centered on whether this represents an early-stage institutional allocation or a momentum-driven squeeze.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending due to intense speculation surrounding an imminent buyout and the anticipation of the 80th clinical trial event. Investors are actively discussing the potential impact of institutional accumulation and the company's oncology pipeline, leading to high-conviction sentiment and debates over its valuation and regulatory path.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors react to the company's robust Q1 financial results and its continued aggressive oncology expansion, highlighted by the recent acquisition of Terns Pharmaceuticals. The community is actively discussing Merck's long-term pipeline strategy to address the looming patent cliff for Keytruda, while traders monitor the stock's technical chart patterns and M&A activity within the broader biopharma sector.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors rally around the company's immunotherapy platform and pending global expansion, despite ongoing tension with a significant short interest. The community is actively discussing the potential of ANKTIVA and advanced NK cell manufacturing to disrupt oncology markets, with many hopeful that near-term regulatory and partnership catalysts will sustain the stock's current momentum.

ASP Isotopes, Inc. is developing a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy. It operates through the following segments: Nuclear Fuels, Specialist Isotopes and Related Services, and Helium and LNG. The Nuclear Fuels segment engages in the research and development of technologies and methods for producing HALEU and Lithium-6 for the advanced nuclear fuels target market, including the operations of QLE. The Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods for the separation of high-value, low-volume isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Dallas, TX.

ASP Isotopes Inc

ASP Isotopes is trending as investors focus on imminent catalysts, including the highly anticipated spinoff of its nuclear fuel subsidiary, Quantum Leap Energy, and progress on critical helium and isotope production milestones. The community remains hyper-focused on the company's potential to supply advanced materials for the growing AI, semiconductor, and nuclear energy sectors, while actively debating the impact of recent insider activity and broader sector volatility.

Roundhill ETF Trust - Roundhill Memory ETF

The DRAM ETF is attracting intense attention as the memory sector transitions from a traditional commodity cycle to a foundational AI infrastructure play, driven by massive capital expenditures and structural supply shortages. Investors are heavily focused on the upcoming U.S. listing of SK Hynix, which is acting as a major sentiment catalyst and prompting active rotation and volatility across memory-related equities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

T. Rowe Price (TROW) Ascends While Market Falls: Some Facts to Note

T. Rowe Price (TROW) reached $116.11 at the closing of the latest trading day, reflecting a +2.13% change compared to its last close.

Wednesday's ETF with Unusual Volume: TURF

The T Rowe Price Natural Resources ETF is seeing unusually high volume in afternoon trading Wednesday, with over 1.1 million shares traded versus three month average volume of about 40,000. Shares of TURF were up about 0.1% on the day.

Components of that ETF with the highest v...

TAGG: ETF Inflow Alert

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the T. Rowe Price QM U.S. Bond ETF (Symbol: TAGG) where we have detected an approximate $330.2 million dollar inflow -- that's a 16.9% increase week over...

T. ROWE PRICE LAUNCHES SEASON 6 OF "THE ANGLE" PODCAST SERIES WITH INVESTOR-FOCUSED LOOK AT AI ADOPTION

T. ROWE PRICE LAUNCHES SEASON 6 OF "THE ANGLE" PODCAST SERIES WITH INVESTOR-FOCUSED LOOK AT AI ADOPTION T. ROWE PRICE LAUNCHES SEASON 6 OF "THE ANGLE" PODCAST SERIES WITH INVESTOR-FOCUSED LOOK AT AI ADOPTION PR Newswire BALTIMORE, July 1, 2026 New season, "AI at Work: From Promise to Impact...

I Own a Popular Bond ETF With 1 Big Risk -- This Short-Term Bond Fund Might Be a Better Buy

Key PointsThe T. Rowe Price Ultra Short-Term Bond ETF has strongly outperformed the Vanguard Total Bond Market ETF since September 2021...

T. Rowe Price's AUM Growth: Can Diversification Offset Equity Outflows?

TROW's diversified AUM mix is helping cushion equity outflows, but can growth in fixed income, multi-asset and alternatives sustain revenues? Let us find out.

T. ROWE PRICE ANNOUNCES STRATEGIC ENHANCEMENTS TO U.S. INSTITUTIONAL BUSINESS

T. ROWE PRICE ANNOUNCES STRATEGIC ENHANCEMENTS TO U.S. INSTITUTIONAL BUSINESS T. ROWE PRICE ANNOUNCES STRATEGIC ENHANCEMENTS TO U.S. INSTITUTIONAL BUSINESS PR Newswire BALTIMORE, June 22, 2026 New client support model designed to better serve clients, foster deeper partnerships, and drive long-term...

Franklin Climbs to a New 52-Week High: How to Play the Stock Now?

After hitting a new 52-week high, can BEN's expanding alternatives platform and strategic growth initiatives drive further upside? Let us find out.

Asset Managers' May AUM Climbs: TROW, LAZ, BEN & IVZ in Focus

BEN, TROW, LAZ and IVZ see May AUM rise on market gains, ETF demand and steady inflows across retirement and long-term strategies.

T. ROWE PRICE NAMES MIKE BARRY AS HEAD OF GLOBAL MARKETING

T. ROWE PRICE NAMES MIKE BARRY AS HEAD OF GLOBAL MARKETING T. ROWE PRICE NAMES MIKE BARRY AS HEAD OF GLOBAL MARKETING PR Newswire BALTIMORE, June 15, 2026 Appointment reinforces the firm's focus on client engagement, growth, and global reachBALTIMORE, June 15, 2026 /PRNewswire/ -- T. Rowe Price...

T. Rowe Price Group, Inc. engages in the provision of investment management services. It provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. It invests in the public equity and fixed income markets across the globe. The company was founded by Thomas Rowe Price Jr. in 1937 and is headquartered in Baltimore, MD.

T. Rowe Price Group Inc.

Goldman Sachs Investing $1 Billion in T. Rowe Price, Eyes 3.5% Ownership

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$2.34	--	--	N/A
Q1 '26	$2.33	$2.52	8.26%	BEAT
Q4 '25	$2.46	$2.44	-0.68%	MISSED
Q3 '25	$2.54	$2.81	10.69%	BEAT
Q2 '25	$2.15	$2.24	4.31%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

TROWT. Rowe Price Group Inc.

Upcoming Earnings: Q2 '26

Historical Earnings

Latest TROW News